• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Cumenes

Recent Advances in the Study of Benzoic acid, 2-methyl-6-(1-methylethyl)- (CAS: 220847-57-4) in Chemical Biology and Pharmaceutical Research

Benzoic acid, 2-methyl-6-(1-methylethyl)- (CAS: 220847-57-4), a derivative of benzoic acid, has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, characterized by its isopropyl and methyl substituents on the aromatic ring, exhibits notable biological activities, making it a promising candidate for drug development. Recent studies have explored its pharmacological properties, including anti-inflammatory, antimicrobial, and anticancer effects, as well as its role in modulating enzyme activity and cellular pathways.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers investigated the molecular interactions of Benzoic acid, 2-methyl-6-(1-methylethyl)- with cyclooxygenase-2 (COX-2), a key enzyme involved in inflammation. The study utilized molecular docking simulations and in vitro assays to demonstrate the compound's ability to inhibit COX-2 activity, suggesting its potential as a non-steroidal anti-inflammatory drug (NSAID) candidate. The findings were further supported by pharmacokinetic analyses, which indicated favorable absorption and metabolic stability in preclinical models.

Another notable advancement was reported in a 2024 ACS Chemical Biology article, where the compound's antimicrobial properties were evaluated against multidrug-resistant bacterial strains. The research highlighted its efficacy in disrupting bacterial cell membranes, particularly in Gram-positive pathogens, through a mechanism involving membrane depolarization. This discovery opens new avenues for developing novel antibiotics to address the growing challenge of antimicrobial resistance.

Beyond its therapeutic potential, Benzoic acid, 2-methyl-6-(1-methylethyl)- has also been explored for its role in chemical biology as a scaffold for designing enzyme inhibitors. A recent Nature Chemical Biology study (2024) demonstrated its utility in synthesizing selective inhibitors for protein kinases, which are critical targets in cancer therapy. The compound's structural flexibility allowed for the development of derivatives with enhanced binding affinity and specificity, paving the way for targeted kinase inhibitors with reduced off-target effects.

In conclusion, the growing body of research on Benzoic acid, 2-methyl-6-(1-methylethyl)- (CAS: 220847-57-4) underscores its multifaceted applications in drug discovery and chemical biology. Its anti-inflammatory, antimicrobial, and anticancer properties, coupled with its versatility as a molecular scaffold, position it as a valuable compound for future pharmaceutical innovations. Further studies are warranted to optimize its pharmacokinetic profile and evaluate its clinical potential in human trials.

• 2438-04-2(2-Isopropylbenzoic acid)
• 1077-58-3(2-tert-butylbenzoic acid)
• 49623-71-4(2,4,6-Triisopropylbenzoic acid)
• 3158-74-5(2-Cyclopropylbenzoic acid)
• 92035-95-5(2,6-Diisopropylbenzoic Acid)
• 612-19-1(2-Ethylbenzoic acid)
• 612-35-1(2-Benzylbenzoic acid)
• 108961-55-3(2,4-Bis(propan-2-yl)benzoic Acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)